1. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
- Author
-
Beena Kumar, David Clouston, Kate Harvey, Jia-Min B Pang, Jane Beith, Jane E. Armes, Sunil R. Lakhani, Shona Hendry, Christina I. Selinger, Stephen B. Fox, Charles Chan, Wendy A. Raymond, Wendy A Cooper, Samuel Roberts-Thomson, Marian L. Burr, Peter Button, David J Byrne, Sandra A O'Toole, Ewan K.A. Millar, Vanathi Sivasubramaniam, and Belinda Castles
- Subjects
Adult ,PD-L1 ,Oncology ,medicine.medical_specialty ,Concordance ,Triple Negative Breast Neoplasms ,B7-H1 Antigen ,Pathology and Forensic Medicine ,Breast cancer ,Atezolizumab ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Triple-negative breast cancer ,Aged ,Aged, 80 and over ,Observer Variation ,business.industry ,BRCA mutation ,Antibodies, Monoclonal ,Original Articles ,Middle Aged ,medicine.disease ,Immunohistochemistry ,SP142 ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,triple-negative breast cancer ,Female ,Surgery ,Triple-Negative Breast Carcinoma ,Anatomy ,business ,Breast carcinoma - Abstract
Supplemental Digital Content is available in the text., SP142 programmed cell death ligand 1 (PD-L1) status predicts response to atezolizumab in triple-negative breast carcinoma (TNBC). Prevalence of VENTANA PD-L1 (SP142) Assay positivity, concordance with the VENTANA PD-L1 (SP263) Assay and Dako PD-L1 IHC 22C3 pharmDx assay, and association with clinicopathologic features were assessed in 447 TNBCs. SP142 PD-L1 intraobserver and interobserver agreement was investigated in a subset of 60 TNBCs, with scores enriched around the 1% cutoff. The effect of a 1-hour training video on pretraining and posttraining scores was ascertained. At a 1% cutoff, 34.2% of tumors were SP142 PD-L1 positive. SP142 PD-L1 positivity was significantly associated with tumor-infiltrating lymphocytes (P
- Published
- 2021
- Full Text
- View/download PDF